EU Decision Time On Broader Indication For AbbVie’s Skyrizi
Verdict Also Due On Expanding Olumiant’s Use As COVID-19 Treatment
Executive Summary
The European Medicines Agency is meeting this week to consider applications to broaden the use of approved drugs to include new indications in the EU.
You may also be interested in...
AbbVie Remains Confident About Rinvoq Despite Coming Safety Labeling Update
A safety-related FDA revision of Rinvoq’s label in rheumatoid arthritis is a perceived threat to the JAK inhibitor’s growth, but it and fellow immunology asset Skyrizi produced another strong sales quarter.
Sanofi Genzyme’s Treatment For Pompe Disease On Track For EU Approval
EU reviewers have recommended marketing approval for two new medicines, but have turned down another product.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.